FRANKLIN TEMPLETON ETF TR - GENOMIC ADV ETF (HELX)

Q4 2024 13F Holders as of 31 Dec 2024

Type / Class
Equity / GENOMIC ADV ETF
Number of holders
9
Total 13F shares, excl. options
103,042
Shares change
+55,369
Total reported value, excl. options
$2,973,230
Value change
+$1,597,396
Number of buys
6
Price
$28.85

Institutional Holders of FRANKLIN TEMPLETON ETF TR - GENOMIC ADV ETF (HELX) as of Q4 2024

As of 31 Dec 2024 FRANKLIN TEMPLETON ETF TR - GENOMIC ADV ETF (HELX) had 9 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions held a total of 103,042 shares of stock of the company.
Largest 8 holders included JANE STREET GROUP, LLC, Glenview Trust co, LPL Financial LLC, CITADEL ADVISORS LLC, UBS Group AG, HALBERT HARGROVE GLOBAL ADVISORS, LLC, Royal Bank of Canada, and HARBOUR INVESTMENTS, INC..
This table shows 8 institutional shareholders of the security as of 31 Dec 2024.
Investor Option Weight % Change % Value $ * Price $ Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.